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Abstract
Optical imaging using multiphoton microscopy and whole body near infrared imaging has become a routine part of
biomedical research. However, optical imaging methods rely on the availability of either small molecule reporters or
genetically encoded fluorescent proteins, which are challenging and time consuming to develop. While directly labeled
antibodies can also be used as imaging agents, antibodies are species specific, can typically not be tagged with multiple
fluorescent reporters without interfering with target binding, and are bioactive, almost always eliciting a biological response
and thereby influencing the process that is being studied. We examined the possibility of developing highly specific and
sensitive optical imaging agents using aptamer technology. We developed a fluorescently tagged anti-Ab RNA aptamer,
b55, which binds amyloid plaques in both ex vivo human Alzheimer’s disease brain tissue and in vivo APP/PS1 transgenic
mice. Diffuse b55 positive halos, attributed to oligomeric Ab, were observed surrounding the methoxy-XO4 positive plaque
cores. Dot blots of synthetic Ab aggregates provide further evidence that b55 binds both fibrillar and non-fibrillar Ab. The
high binding affinity, the ease of probe development, and the ability to incorporate multiple and multimodal imaging
reporters suggest that RNA aptamers may have complementary and perhaps advantageous properties compared to
conventional optical imaging probes and reporters.
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Introduction
An emerging class of novel molecular probes based on RNA or
DNA aptamers may offer significant advantages as both thera-
peutic and diagnostic imaging agents [1–4]. Very large RNA
libraries can be rapidly screened to identify sequences that bind a
given molecule with high affinity using Selective Evolution of
Ligands by EXponential enrichment (SELEX) [5,6]. The affinities
and specificities of RNA aptamers are comparable to or even
better than those of antibodies [1,7]. Aptamers can fold back into
their natural conformation after denaturation and are stable in the
reducing environment of the cell [3]. Aptamers are much smaller
than antibodies, thereby improving their biodistribution [3,8].
Aptamers can be delivered to cells using viral vectors [4,9].
Aptamers can also be made by chemical synthesis, which allows
for tailor-made modifications and avoids biological contamination.
Imaging agents can be easily incorporated into aptamers using
labeled nucleotides, providing the potential for multiplexing and
for tuning reagents to the imaging platform. For example,
fluorescein-tagged nucleotides can be used for 2-photon imaging,
Cy5-tagged nucleotides for near infrared imaging,
18F-labled
nucleotides for positron emission tomography (PET) imaging, and
19F-labeled nucleotides for
19F magnetic resonance imaging
(MRI). Aptamers may also provide powerful tools for developing
therapeutic agents [3,4]. Aptamers have even been selected that
cross the blood-brain barrier [10]. Finally, aptamers typically have
low or no immunogenicity [3,11]. As a test of the idea that
aptamers could be used as a new in vivo optical imaging tool, we
have investigated the use of a fluorescently labeled anti-Ab
aptamer for imaging both amyloid plaques and oligomeric Ab in
Alzheimer’s disease (AD) mouse models.
Increasing evidence suggests that soluble oligomeric Ab is
synaptotoxic and plays a central role in the early pathogenesis of
AD [12,13]. Studies in neuronal cultures and organotypic slices
demonstrated that soluble forms of Ab induce synaptic changes
and dendritic spine loss and are toxic to mature central nervous
system neurons [14–16]. Shankar et al demonstrated that Ab
dimers, but not insoluble plaque cores, impaired long-term
potentiation, lowered the threshold for induction of long-term
depression, and reduced dendritic spine density in normal mouse
hippocampus [17]. Similarly, the presence of a 56-kDa Ab
assembly has been correlated with memory loss in Tg2576
transgenic mouse models of AD [18,19], while Tris-buffered saline
(TBS) soluble Ab from Alzheimer’s disease brain has been shown
to disrupt the memory of a learned behavior in normal rats [17].
Koffie et al demonstrated that oligomeric Ab, present in a halo
surrounding dense core plaques, is associated with postsynaptic
densities and correlates with excitatory synapse loss near amyloid
plaques [20,21]. Finally, recent studies of transgenic mice that co-
express mutant forms of amyloid precursor protein (APP) and tau
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e89901have demonstrated that oligomeric Ab accumulation, but not total
amyloid plaque burden, correlates with neuronal loss and
inflammatory response [22]. These studies suggest that amyloid
plaques serve as reservoirs of oligomeric Ab and that oligomeric
Ab is synaptotoxic. Given this evidence of a direct role of Ab
oligomers in AD, there is a great need for new reagents capable of
detecting not only mature amyloid plaques but also oligomeric
forms of Ab.
A large number of antibodies that recognize a variety of
epitopes of different Ab assemblies, including low molecular
weight Ab oligomers, have been developed and used extensively in
ex vivo studies [23–31]. However, the use of antibodies for in vivo
studies is complicated by the plaque clearance that is induced by
anti-Ab antibodies [32]. In addition, the incorporation of multiple
optical labels, to provide for increased detection sensitivity,
typically significantly reduces the antibody binding affinity. A
small molecule positron emission tomography (PET) tracer for
imaging amyloid plaques that crosses the blood-brain barrier
(BBB), Pittsburgh Compound-B (PiB), was developed and has been
successfully used in many clinical studies [33]. Similarly, a small
molecule fluorescent derivative of Congo Red, methoxy-XO4, has
been extensively used in optical studies of AD transgenic mouse
models [34]. However, while these small molecule amyloid probes
do cross the BBB and are able to detect fibrillar Ab, they do not
detect oligomeric Ab. If oligomeric Ab burden is more directly
related to synaptic toxicity and the risk of developing AD, a probe
that bound Ab oligomers might provide a more specific reporter
for the risk of developing AD. Approaches to image oligomeric
Ab, even if only in experimental models, may prove important to
inform our understanding of the pathobiology of these species
in vitro and in vivo.
A novel RNA aptamer, b55, generated from a SELEX screen
against monomeric Ab1–40 was previously shown to bind synthetic
amyloid fibrils [35]. Similar SELEX screens against covalently
stabilized Ab trimers [36] and against Ab1–40 conjugated to
colloidal gold nanoparticles [37] have been performed. More
recently, a DNA aptamer selected against a-synuclein was shown
to also bind oligomeric Ab [38]. However, to date no ex vivo stains
of human AD brain tissue or in vivo mouse studies in amyloid-
laden transgenic AD models have been performed with aptamer
probes. Here we demonstrate for the first time the ability of b55 to
bind amyloid plaques in ex vivo human AD brain tissue and in live
transgenic mouse models of AD. Furthermore, we demonstrate
that b55 binds Ab oligomers and is able to visualize the oligomeric
halo surrounding the dense cores of amyloid plaques. This is the
first use of an aptamer as an in vivo optical imaging probe.
Materials and Methods
Synthesis of Labeled RNA Aptamers
Double-stranded DNA template (132 bp) was synthesized by
polymerase chain reaction of the 76 mer 59 ends of b55 and its
reverse complement (Operon Biotechnologies, Huntsville, AL),
which contain a 20 bp overlap. The DNA sequence (Table 1)
included a 25 mer T7 RNA polymerase primer. Imaging probes
were introduced into the aptamer by transcription of the DNA
template with T7 RNA polymerase and either biotin-labeled uracil
(Roche Diagnostics, Indianapolis, IN), for ex vivo studies, or
fluorescein-labeled uracil (Roche Diagnostics, Indianapolis, IN),
for in vivo studies, using the Hi-Scribe RNA transcription kit (New
England BioLabs, Ipswich, MA). RNA was purified twice on Mini
Quick-Spin RNA columns (Roche Diagnostics, Indianapolis, IN)
to ensure complete removal of unincorporated nucleotides. The
RNA sequence length was characterized both by running the
RNA on a denaturing gel and an Agilent 2100 Bioanalyzer using a
small RNA kit (Agilent Technologies, Santa Clara, CA). Both
methods observed an RNA length of just over 100 nucleotides
consistent with the expected length of 107 nucleotides. RNA
concentrations were determined from the absorbance measured at
260 nm using a Biophotometer (Eppendorf, Hauppauge, New
York). Typical RNA concentrations after purification ranged
between 25–35 mM.
Aptamer Staining of ex vivo AD Brain Tissue
Frozen brain tissue from AD subjects was obtained from the
Massachusetts Alzheimer’s Disease Research Center (http://
madrc.mgh.harvard.edu/) tissue bank. All the study subjects or
their next-of-kin gave written informed consent for the brain
donation at their respective institutions. Tissue was sectioned on a
cryostat at a thickness of 10 mm and fixed for 10 minutes in 4%
paraformaldehyde followed by overnight incubation at 4uC with
either biotinylated b55 aptamer or its reverse complement, b55rc,
used as a control probe. Probes were visualized by reacting with
avidin binding complex followed by tyramide signal amplification
using AlexaFluor 488 tyramide (Invitrogen, Carlsbad, CA). For
slides co-stained with Thioflavin-S, AlexaFluor 594 tyramide
(Invitrogen, Carlsbad, CA) was used for visualizing b55 positive
plaques in the red channel. Slides were coverslipped and imaged
on either an Olympus BX51 fluorescence microscope (Olympus,
Tokyo, Japan) or a Zeiss LSM 510 confocal microscope (Carl Zeiss
MicroImaging, Jena, Germany).
Dot and Western Blot of Synthetic Ab Aggregates
1.1 mM of synthetic Ab1–40 and Ab1–42 (Peptide Institute,
Osaka, Japan) were incubated at 37uC for 3 days with gentle
shaking. 4 ml each of Ab1–40 and Ab1–42 were blotted onto
nitrocellulose paper and allowed to dry. The dot blot was then
stained with biotinylated b55. b55 was visualized by secondary
staining with streptavidin IRDye 700DX (Rockland Immuno-
chemicals, Gilbertsville, PA) and imaged on an Odyssey infrared
imaging system (LI-COR Biosciences, Lincoln, NB). Western blots
of the synthetic Ab reaction mixtures were also performed to
identify the Ab species present in each reaction mixture. Western
blots were stained with 6E10 antibody (1:1000), which is reactive
to amino acid residues 3–8 of Ab. 6E10 was visualized by
secondary staining with anti-mouse IgG antibody conjugated to
IRDye800 (Rockland Immunochemicals, Gilbertsville, PA) and
imaged on an Odyssey infrared imaging system (LI-COR
Biosciences, Lincoln, NB).
In vivo 2-photon Imaging of APP/PS1 Transgenic Mice
In vivo multiphoton images of optical fluorophores were
obtained in real time using an Olympus Fluoview 1000 MPE
with prechirp optics mounted on an Olympus BX61WI upright
microscope. APP/PS1 transgenic mice which coexpress mutant
alleles of amyloid precursor protein (APP) and presenilin (strain
B6C3-Tg[APPswe, PSEN1dE9]85Dbo/J, Jackson Laboratory,
Bar Harbor, ME) [39] were used for all imaging experiments.
After craniotomy, 20 mg of fluorescein labeled aptamer probe
(either b55 or b55rc) was topically applied to the mouse brain for
30 minutes. The surface of the brain was then flushed with
artificial cerebral spinal fluid, followed by placement of the
coverslip window. A wax ring was placed on the edges of the
coverslip covering the craniotomy window and was filled with
distilled water to maximize contact between water and an
Olympus 206 dipping objective (numerical aperture, 0.95). A
mode-locked titanium/sapphire laser (MaiTai; Spectra-Physics)
generated two-photon fluorescence with 800-nm excitation, and
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collected emitted light in the ranges of 380–480, 500–540, and
560–650 nm (4). Average power reaching brain tissue in each
experiment ranged from 20 to 60 mW. Images were acquired
between 100 and 500 mm below the surface of the brain. Images
were acquired approximately 1 and 24 hours after topical
application of the aptamer probe. All animal experiments were
approved by the Massachusetts General Hospital Subcommittee
on Research Animal Care (SRAC protocol # 2004N000092) and
conformed to national and institutional guidelines.
Determination of Plaque Contrast-to-noise Ratio
Plaque regions-of-interest (ROI) were determined by threshold-
ing the in vivo images to signals greater than two standard
deviations above the background signal intensity. The plaque
contrast-to-noise ratio (CNR) was calculated from the difference
between the plaque and background signal-to-noise ratios (SNR).
The gold standard used for the identification and counting of the
number of amyloid plaques was the presence of methoxy-XO4
staining.
Results
The predicted secondary structures for the b55 aptamer and a
RNA aptamer synthesized from the reverse complement of the
b55 coding sequence (b55rc), shown in Figure 1, were determined
using the RNAfold Webserver suite of programs (http://rna.tbi.
univie.ac.at/cgi-bin/RNAfold.cgi) [40,41]. The b55rc aptamer
has a very different predicted secondary structure from that of b55
and was used as a control aptamer probe.
The ability of the b55 aptamer to stain amyloid plaques was
demonstrated by staining frozen-section brain tissue from AD
subjects with biotinylated b55 and b55rc aptamers. While plaques
were clearly visible with the b55 aptamer (Figure 2a), only a few
very faint b55rc positive plaques were observed (Figure 2b). A
tissue section co-stained with b55 and Thioflavin-S showed good
colocalization of b55 and Thioflavin-S for amyloid plaques
(Figure 2c).
Dot blots of synthetic Ab1–40 and Ab1–42 that were incubated at
37uC for 3 days were performed to examine the binding of b55 to
different Ab species. b55 staining of both Ab1–40 and Ab1–42 was
observed (Figure 3a). The increased staining observed for Ab1–42 is
consistent with the increased propensity of Ab1–42 to form high
molecular weight (HMW) species relative to Ab1–40 as shown in
the 6E10 western blot of the synthetic Ab reactions (Figure 3b),
where no HMW species were observed for Ab1–40.
Sodium dodecyl sulfate (SDS) western blots of human AD brain
homogenates were stained with both 6E10 monoclonal antibody,
which is reactive to amino acid residues 3–8 of Ab, and
biotinylated b55 (Figure S1 and File S1). b55 and 6E10 bound
many of the same bands, in particular higher molecular weight
oligomer bands between 20 and 60 kDa. In contrast, no binding of
monomeric Ab or soluble APP (sAPP) by b55 was observed. While
some caution must be taken in the interpretation of the western
blot given the documented effects of SDS on Ab oligomer
structure and aggregation [42–46], the colocalization of 6E10 and
b55 bands provides further support for the binding of b55 to Ab
oligomers.
The ability of b55 to bind to plaques in post mortem tissue and
fibrillar and non-fibrillar Ab species on dot blots of synthetic Ab
raised the possibility that the aptamer may label plaques in an
in vivo setting. In vivo 2-photon imaging studies performed in APP/
PS1 transgenic mice, which overexpress mutant alleles of amyloid
precursor protein (APPswe) and presenilin-1 (PS1dE9), showed
that fluorescein-labeled b55 binds amyloid plaques in the cerebral
cortex (Figure 4a) and vasculature (Figure 4b). Plaque staining by
b55 was then compared to plaque staining with methoxy-XO4
(Figure 5). While methoxy-XO4 stained only the dense core of
each plaque, b55 stained both the plaque core and a diffuse halo
surrounding the plaque core (Figure 5c,f).
In vivo b55 plaque staining was compared to plaque staining
with the b55rc control aptamer (Figure 6a). Images were acquired
1 and 24 hours after topical application of the aptamer probes in 2
mice for each aptamer. The b55 aptamer detected almost all of the
methoxy-XO4 positive plaques at both 1-hour (96%) and 24-hour
(83%) time points (see Table 2). In contrast, while the b55rc
control aptamer detected 83% of plaques at the one-hour time
point, only a few faint plaques (,30%) were detected after 24
hours. The contrast-to-noise-ratio (CNR) for b55 positive plaques
was significantly greater (p,0.01) than that for b55rc plaques at
both 1- and 24-hour time points (Table 2 and Figure 6b).
To examine whether b55 induces plaque clearance or
degradation, similar to antibody probes of amyloid plaques,
longitudinal in vivo 2-photon imaging of a 10 month-old APP/PS1
mouse at 1 and 4 days following topical application of b55 was
performed. However, no changes in plaque number or appearance
were observed.
Discussion
RNA aptamers have previously been shown to detect synthetic
Ab fibrils with very high sensitivity [35–37]. These RNA aptamers
were selected in SELEX screens against either Ab monomers or
low molecular weight Ab oligomers and may therefore prove to be
excellent probes for detecting not only amyloid plaques, but also
Ab oligomers. Here we examined the ability of b55, an aptamer
previously selected in a SELEX screen against synthetic Ab1–40
[35], to bind oligomeric Ab and amyloid plaques in ex vivo human
AD brain tissue slices and in an in vivo transgenic mouse model of
AD.
As demonstrated in Figure 2, robust staining of amyloid plaques
by b55 was observed in ex vivo human AD brain tissue slices, while
only a few very faint plaques were observed with the b55rc control
aptamer. In addition, costaining with Thioflavin-S demonstrated
that b55-positive plaques colocalize with Thioflavin-S stained
plaques (Figure 2c). Similarly, b55 bound amyloid plaques in the
cortex and vasculature of live APP/PS1 mice (Figure 4) and
colocalized with methoxy-XO4 staining (Figure 5). Interestingly,
b55 stained not only the plaque core, but also labeled a diffuse
halo surrounding the core that was not observed with methoxy-
XO4. These data suggest that b55 may bind smaller aggregates of
Ab surrounding the dense core, including oligomeric Ab.
Table 1. DNA sequence for the b55 aptamer including the T7 polymerase primer, highlighted in bold text.
59-GCG TAA TAC GAC TCA CTA TAG GGC GGG GAA TTC GAG CTC GGT ACC TTT ACC GTA AGG CCT GTC TTC GTT TGA CAG CGG CTT GTT GAC CCT CAC ACT TTG
TAC CTG CTG CCA ACT GCA GGC ATG CAA GCT TGG-39
doi:10.1371/journal.pone.0089901.t001
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blots of synthetic Ab aggregates were performed. Strong b55
staining of Ab1–42 aggregates was observed with fainter staining of
Ab1–40 aggregates (Figure 3a). The difference in staining is
attributed to the increased propensity of Ab1–42 to form fibrils
relative to Ab1–40. This is demonstrated in the 6E10 western blot
of the Ab samples, where a large number of high molecular weight
species were observed for Ab1–42, but not Ab1–40 (Figure 3b). The
Ab1–40 dot blot staining therefore indicates that b55 binds low
molecular weight, non-fibrillar Ab species. In accord with these
findings, Tsukakoshi et al observed binding of a DNA aptamer to
oligomeric Ab1–40 [38].
The in vivo optical imaging data indicates that both b55 and
b55rc control aptamer bind plaques. This is consistent with
previous studies that demonstrated that RNA aptamers in general
have a high affinity for amyloidigenic structures. In a SELEX
screen for Ab targeted RNA aptamers, Rahimi et al showed that
both the naı ¨ve SELEX library and the final selected aptamers
bound a large number of different amyloidogenic proteins,
suggesting that RNA has an intrinsically high affinity for
amyloidogenic, b-sheet structures [36]. Further support for the
affinity of RNA for amyloidogenic structures is provided by a
recent molecular modeling study that observed a very high
homology between Ab and the RNA binding protein AF-Sm1 [47]
and by the fact that senile plaques have been found to contain high
Figure 1. Predicted Secondary Structure of RNA Aptamers. Predicted secondary structure of the b55 (left) and b55rc (right) aptamer probes
with base pair probability indicated by the color scale bar. Minimum free energy structures were determined using the RNAfold Webserver suite of
programs.
doi:10.1371/journal.pone.0089901.g001
Figure 2. b55 Staining of Amyloid Plaques in Ex Vivo Human AD Brain Tissue. Merged red and green channel confocal images of frozen-
section human AD brain tissue stained with biotinylated b55 (a) and b55rc (b). b55 positive plaques (green) were clearly visible, while only a few very
faint b55rc positive plaques were observed. Background auto-fluorescence, observed in both red and green channels, is shown in yellow. (c)
Fluorescence images of human AD brain tissue costained with biotinylated-b55 (red) and Thioflavin-S (green). b55 colocalized with Thioflavin-S
positive plaques. (Scale bars: 50 mm).
doi:10.1371/journal.pone.0089901.g002
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structures would explain the in vivo plaque binding observed for
the b55rc aptamer that was used as a control in our study.
However, while RNA may have some affinity for beta sheet
structures, the fact that a significantly increased CNR was
observed for b55 plaques compared to b55rc plaques in the
in vivo multiphoton images (Figure 6 and Table 2), at both early
and late imaging time points, suggests that there are differences in
binding affinity with b55 having a significantly greater affinity than
b55rc. This is consistent with the fact that only a few very faint,
b55rc-positive plaques were visible in the ex vivo human AD brain
tissue (Figure 2b). In addition, Ylera measured aptamer dissoci-
ation constants (Kd) for binding to Ab using affinity chromatog-
raphy and while a Kd of 29 nM was determined for b55 no Kd
was measureable for the RNA aptamer pool obtained from the
first SELEX cycle [51], again indicating that RNA aptamers do
display significant differences in binding affinity.
While the large molecular weight of the b55 aptamer (34 kDa)
precludes its crossing the blood-brain barrier (BBB), a recent study
by Cheng et al, in which an in vivo SELEX screen for a BBB
penetrating aptamer was performed, did find an aptamer (A15)
capable of crossing the BBB [10]. While the exact mechanism of
the brain uptake of the BBB penetrating aptamer is unclear, given
the large molecular weight of the aptamer (23 kDa) the most likely
mechanism is by receptor-mediated transcytosis. Studies are
currently underway to investigate the possibility of designing a
fusion aptamer consisting of BBB penetrating and amyloid binding
domains that would allow aptamers to be delivered non-invasively
to the brain.
These studies demonstrate the great potential of RNA aptamers
as in vivo and ex vivo imaging probes. One third of uracil nucleotides
were fluorescein labeled, corresponding to a total of 10 fluoresceins
per aptamer, providing high detection sensitivity. The incorpora-
tion of multiple fluorescein labels did not interfere with the
amyloid binding. The fact that the fluorescein-labeled aptamer still
bound plaques with high affinity is likely due to the fact that only a
relatively small conserved region of the aptamer is required for
binding. A significant fraction of the aptamer consists of sequences
required for the selection/amplification process in the SELEX
screen. In addition, topical application of b55 did not result in
Figure 3. b55 Staining of Dot Blots of Synthetic Ab Aggregates. (a) Dot blot of synthetic Ab1–42 and Ab1–40 aggregates probed with
biotinylated-b55. (b) Western blot of the synthetic Ab1–42 and Ab1–40 aggregates probed with 6E10 antibody. The increased staining of Ab1–42
aggregates in the dot blot relative to Ab1–40 aggregates is consistent with the greater fibril and high molecular weight oligomer composition of Ab1–
42 aggregates observed in the western blot.
doi:10.1371/journal.pone.0089901.g003
Figure 4. In Vivo Imaging of b55 Positive Amyloid Plaques. In vivo 2-photon microscopy images from an 18 month old APP/PS1 transgenic
mouse obtained 1 hour after topical application of fluorescein-labeled b55 (a,b). Texas Red labeled dextran was intravenously injected for
visualization of blood vessels. b55 positive plaques and cerebral amyloid angiopathy are clearly visible in the cortex (a) and vasculature (b),
respectively. (Scale bars: 20 mm).
doi:10.1371/journal.pone.0089901.g004
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PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e89901Figure 5. Colocalization of b55 and Methoxy-XO4 Positive Amyloid Plaques. In vivo 2-photon microscopy plaque images from a 7 month
old APP/PS1 transgenic mouse acquired 1 hour after topical application of fluorescein-labeled b55 (a,d) and 1 day after intraperitoneal injection of
methoxy-XO4 (b,e). While methoxy-XO4 stains only the dense core of the plaque, b55 stains both the plaque core and a diffuse halo surrounding the
plaque (c,f). (Scale bars: 20 mm).
doi:10.1371/journal.pone.0089901.g005
Figure 6. Contrast-to-Noise Ratio for b55 and b55rc Positive Amyloid Plaques. (a) Representative in vivo 2-photon microscopy images from
7.5 month old APP/PS1 transgenic mice acquired 1 hour (left column) and 24 hours (right column) after topical application of either fluorescein-
labeled b55 (top row) or b55rc (bottom row). Most b55 plaques were still visible 24 hours after topical application. In contrast, only a small number of
very faint b55rc plaques were still visible after 24 hours. (b) Average plaque contrast-to-noise ratio (CNR) observed 1 hour and 24 hours following
topical application of fluorescein-labeled b55 (n=2) or b55rc (n=2). b55 positive plaques had a significantly greater CNR than b55rc plaques (p,0.01)
at both time points. (Scale bars: 50 mm).
doi:10.1371/journal.pone.0089901.g006
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relatively inert biologically, in contrast to antibody probes that
induce an inflammatory response and plaque clearance [32].
Finally, aptamers can be made with a variety of multimodal probes
for optical, MR or PET imaging. Uracil labeled with a whole host
of different optical tags is readily available and can easily be
incorporated into the aptamer. In addition, cytosine and uracil
nucleotides fluorinated at the 29-pyramidine position, which are
commercially available, can be used to make RNAse resistant
aptamers that may also be detectable by
19F MRI. A previous
study with a cold
19F PET probe specific for amyloid plaques was
able to detect plaques using
19F MRI, however, with only a single
19F per probe molecule the sensitivity was very low and an
extremely long MRI acquisition time of 90 minutes was required
to obtain low resolution
19F images [52]. However, significantly
greater
19F MRI sensitivity, and hence decreased signal acquisition
times, would potentially be achievable with fluorinated b55, which
contains 30 cytosine and 30 uracil nucleotides for a total of 60
19F
nuclei. Finally, a PET aptamer probe could be generated either by
incorporating 59-ethynyl-uridine, a commercially available uracil
analog, into the RNA aptamer followed by click chemistry
reaction with
18F-azide or by end labeling the aptamer with
64Cu.
Conclusions
In summary, the b55 aptamer binds amyloid plaques in both ex
vivo human AD brain tissue and in vivo APP/PS1 transgenic mice.
Diffuse halos surrounding the methoxy-XO4 positive plaque cores
were observed with b55 in vivo, which may represent oligomeric
Ab. The unprotected RNA aptamer appears to be quite stable and
detectable for at least 24 hours under in vivo conditions when
bound to amyloid plaques. In addition, no detectable tissue
response to the aptamer application, such as plaque clearance, was
detected. These data suggest that Ab-targeted aptamers bind
oligomeric Ab and may be useful reagents for imaging both
fibrillar and non-fibrillar Ab. Moreover, these data illustrate the
broader principle that RNA aptamers, which are nearly infinitely
adaptable using SELEX technologies and that can be labeled with
any number of off-the-shelf multimodal imaging agents (fluor-
ophores, biotin, radioisotopes or epitope tags), can be developed
with high enough detection sensitivity and selectivity to rival
antibodies and small molecules in in vivo and ex vivo imaging
studies.
Supporting Information
Figure S1 b55 Staining of Western Blot of Human AD
Brain Tissue Extracts. Western blot of human AD brain tissue
extracts obtained after sequential treatment with TBS, 2% Triton
X-100, 0.5% SDS, and 70% formic acid. The western blot was
probed with both 6E10 antibody (green) and biotinylated-b55
(red). b55 binds many of the same bands as 6E10 (yellow asterisks).
The green and red asterisks indicate bands unique to 6E10 or b55,
respectively. Faint bands at ,8 and 16 kDa were visible in the b55
image (arrows) of the SDS soluble fraction.
(TIF)
File S1 Methods and Results for b55 Staining of Western
Blot of Human AD Brain Tissue Extracts.
(DOCX)
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